Characterization of tetrandrine, a potent inhibitor of P-glycoprotein-mediated multidrug resistance

[1]  L. Fu,et al.  Experimental chemotherapy against xenografts derived from multidrug resistant KBv200 cells and parental drug-sensitive KB cells in nude mice by annonaceous acetogenin 89-2. , 2003, Yao xue xue bao = Acta pharmaceutica Sinica.

[2]  J. Lella.  Constructing History in Biography: A Symposium on William Osler: A Life in Medicine: Introduction , 2001, Bulletin of the history of medicine.

[3]  I K Pajeva,et al.  Structure-activity relationships of multidrug resistance reversers. , 2001, Current medicinal chemistry.

[4]  D. Lawrence,et al.  Structure-activity studies of substituted quinoxalinones as multiple-drug-resistance antagonists. , 2001, Journal of medicinal chemistry.

[5]  T. Motoji,et al.  Multidrug resistance of acute leukemia and a strategy to overcome it. , 2000, International journal of hematology.

[6]  J. Molnár,et al.  Reversal of multidrug resistance of tumor cells. , 2000, Anticancer research.

[7]  L. Mayer,et al.  Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[8]  M. J. Newman,et al.  Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance. , 2000, Cancer research.

[9]  P. Sonneveld,et al.  The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia. , 2000, International journal of clinical pharmacology and therapeutics.

[10]  T. Uchiumi,et al.  Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. , 1999, Molecular pharmacology.

[11]  M. Volm,et al.  Multidrug resistance and its reversal. , 1998, Anticancer research.

[12]  P. Atadja,et al.  PSC-833, a frontier in modulation of P-glycoprotein mediated multidrug resistance , 1998, Cancer and Metastasis Reviews.

[13]  B. Sikic.  Pharmacologic approaches to reversing multidrug resistance. , 1997, Seminars in hematology.

[14]  T. Furukawa,et al.  Reversal of multidrug resistance-associated protein-mediated drug resistance by the pyridine analog PAK-104P. , 1997, Molecular pharmacology.

[15]  J. Saunders,et al.  Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro. , 1997, Anti-cancer drugs.

[16]  R. Pirker,et al.  Multidrug resistance in leukemias and its reversal. , 1996, Leukemia & lymphoma.

[17]  A. Dantzig,et al.  Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. , 1996, Cancer research.

[18]  P. Wigler.  Cellular drug efflux and reversal therapy of cancer , 1996, Journal of bioenergetics and biomembranes.

[19]  C. Vergely,et al.  In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. , 1993, Cancer research.

[20]  M. Slovak,et al.  Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. , 1993, Cancer research.

[21]  W. Mackinnon,et al.  Plasma membrane lipid composition of vinblastine sensitive and resistant human leukaemic lymphoblasts , 1988, International journal of cancer.

[22]  James B. Mitchell,et al.  Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. , 1987, Cancer research.

[23]  J. Minna,et al.  Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity. , 1987, Cancer research.

[24]  T. Tsuruo,et al.  Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. , 1981, Cancer research.

[25]  G. Feng,et al.  Establishment of the model of KBv200 nude mice xenograft and studies on its characterization of multidrug resistance , 2000 .

[26]  C. Ardiet,et al.  Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors , 1998, Cancer Chemotherapy and Pharmacology.

[27]  B. Sikic,et al.  Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein , 1997, Cancer Chemotherapy and Pharmacology.

[28]  V. Ling.  Multidrug resistance: molecular mechanisms and clinical relevance , 1997, Cancer Chemotherapy and Pharmacology.

[29]  C. Shih,et al.  Pharmacological characterization of LY335979: a potent cyclopropyldibenzosuberane modulator of P-glycoprotein. , 1997, Advances in enzyme regulation.

[30]  X. Ji,et al.  [Vincristine-resistant human KB cell line and mechanism of multidrug resistance]. , 1994, Yao xue xue bao = Acta pharmaceutica Sinica.